武汉科前生物股份有限公司（下称"公司"）于 2023 年 8 月 26 日以现场表决的形式召开第三届监事会第二十七次会议（下称"本次 会议"）。本次会议通知于 2023 年 8 月 16 日以邮件、电话的方式向 各位监事发出，本次会议由监事会主席吴斌先生主持，本次会议应参 与表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、召开程 序均符合《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）等法律、法 规和规范性文件以及《公司章程》的规定。 二、监事会会议审议情况 经与会监事审议，作出决议如下： （一）审议通过《关于公司<2023 年半年度报告>及其摘要的议 案》 证券代码：688526 证券简称：科前生物 公告编号：2023-043 武汉科前生物股份有限公司 第三届监事会第二十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 监事会认为：公司按照募集资金存放与使用的相关法律法规和规 范性文件及公司《募集资金管理制度》的 ...

证券代码：688526 证券简称：科前生物 公告编号：2023-045 武汉科前生物股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性 依法承担法律责任。 武汉科前生物股份有限公司（下称"公司"）2023 年 8 月 26 日 召开第三届董事会第三十次会议、第三届监事会第二十七次会议审 议通过了《关于公司使用闲置募集资金进行现金管理的议案》，同 意公司使用额度不超过人民币 40,000 万元（含本数）的闲置募集资 金在确保不影响募集资金投资项目进度、不影响公司正常生产经营 及确保资金安全的情况下进行现金管理，在上述额度范围内，资金 可以滚动使用，使用期限自公司董事会审议通过之日起 12 个月内有 效。董事会授权董事长或董事长授权人士在上述额度范围内行使投 资决策权并签署相关合同文件,具体事项由公司财务部负责组织实施。 独立董事发表了明确同意的独立意见，招商证券股份有限公司（以 下简称"保荐机构"）对本事项出具了明确的核查意见。 一、募集资金基本情况 （一）公司首次公开发行股票募集资金到位情况 ...

招商证券股份有限公司关于武汉科前生物股份有限公司 使用闲置募集资金进行现金管理的核查意见 招商证券股份有限公司（以下简称"招商证券"或"保荐机构"）作为武汉 科前生物股份有限公司（以下简称"科前生物"或"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《上海证券交易所科创板股票上市规则》《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、行政法规、 部门规章及业务规则，对科前生物拟使用闲置募集资金进行现金管理的事项进行 了认真、审慎的核查，核查情况如下： 一、募集资金基本情况 （一）公司首次公开发行股票募集资金到位情况 经中国证券监督管理委员会《关于同意武汉科前生物股份有限公司首次公开 发行股票注册的批复》(证监许可[2020]1909 号) ，同意公司首次公开发行股票 的注册申请，并经上海证券交易所同意，公司首次公开发行人民币普通股 10,500 万股，发行价格 11.69 元/股，新股发行募集资金总额为 122,745 万元，扣除发 行费用 8,571.72 万元后，募集资金净额为 114,173.28 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求（2022 年修订）》和《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》等有关规定，现将本公司 2023 年半年度募集资金存放 与使用情况说明如下： 一、 募集资金基本情况 （一） 实际募集资金金额、资金到位时间 证券代码：688526 证券简称：科前生物 公告编号：2023-044 武汉科前生物股份有限公司 2023 年半年度募集资金存放与实际使用情况的 专项报告 经中国证券监督管理委员会《关于同意武汉科前生物股份有限公司首次 公开发行股票注册的批复》（证监许可（2020）1909 号），并经上海证券交 易所同意，本公司由主承销商招商证券股份有限公司采用向战略投资者定向 配售、网下向符合条件的投资者询价配售和网上向持有上海市场非限售 A 股 股份和非限售存托凭证市值的社会公众投资者定价发行相结合的方式，发行 了普通股（A 股）股票 10,500.00 万股，发行价为每股人民币 1 ...

武汉科前生物股份有限公司部分高级管理人员集 中竞价减持计划时间届满未减持股份的结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 高级管理人员持股的基本情况 本次减持计划实施前，武汉科前生物股份有限公司（下称"公司"）副总经 理徐高原先生直接持有公司股份 2,641,497 股，占公司总股本的 0.5666%；公司 副总经理陈关平先生直接持有公司股份 1,350,058 股，占公司总股本的 0.2896%。 上述股份均为公司首次公开发行前持有的股份，且已于 2021 年 9 月 22 日解除限 售并上市流通。 集中竞价减持计划的实施结果情况 证券代码：688526 证券简称：科前生物 公告编号：2023-042 （一）大股东及董监高因以下事项披露集中竞价减持计划实施结果： 披露的减持时间区间届满 | 股东名称 | 减持数量 | | 减持比例 | 减持期间 | 减持方式 | 减持价格区间 | 减持总金 | | 减持完成情况 | 当前持股数 | 当前持股 | | --- | --- | --- ...

证券代码：688526 证券简称：科前生物 公告编号：2023-024 武汉科前生物股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 副总经理、财务总监：钟鸣先生 武汉科前生物股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 09 日 上午 11:00-12:00 举行 2022 年度业绩暨现金分红说明会，就投 资者关心的问题进行交流。 会议召开时间：2023 年 05 月 09 日(星期二) 上午 11:00- 12:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 29 日(星期六)至 05 月 08 日(星期 一)16:00 前登录上证路演中心网 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 279,514,834.18, representing a year-on-year increase of 37.92%[5] - The net profit attributable to shareholders for the same period was CNY 135,537,098.41, reflecting a growth of 49.33% compared to the previous year[10] - Basic and diluted earnings per share were both CNY 0.29, marking a 45.00% increase year-on-year[6] - Total operating revenue for Q1 2023 reached ¥279,514,834.18, a 38% increase from ¥202,659,616.48 in Q1 2022[20] - Net profit for Q1 2023 was ¥135,431,910.74, compared to ¥90,760,001.56 in Q1 2022, representing a 49% growth[21] - The company reported a total profit of ¥156,199,066.47 for Q1 2023, up from ¥102,776,638.28 in Q1 2022, marking a 52% increase[21] Cash Flow - The net cash flow from operating activities reached CNY 178,103,336.61, an increase of 67.43% due to higher sales revenue[6] - The net cash flow from operating activities for Q1 2023 was $178.1 million, an increase of 67.5% compared to $106.4 million in Q1 2022[24] - Cash inflow from operating activities in Q1 2023 was ¥358,807,595.18, compared to ¥296,350,484.11 in Q1 2022, indicating a 21% increase[23] - The net cash flow from investment activities was -$20.8 million, an improvement from -$92.1 million in Q1 2022[24] - Cash inflow from financing activities totaled $115.0 million, compared to $60.7 million in the same quarter last year, marking an increase of 89.5%[24] - The net increase in cash and cash equivalents for the quarter was $270.3 million, contrasting with a decrease of $14.2 million in the previous year[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 4,672,235,560.78, up 6.41% from the end of the previous year[6] - The company's total assets reached CNY 4,672,235,560.78, an increase from CNY 4,390,641,791.92 on December 31, 2022, reflecting a growth of approximately 6.4%[16] - The company's total liabilities increased to CNY 769,539,959.37 from CNY 623,841,368.92, representing a rise of about 23.3%[17] - Total liabilities as of Q1 2023 amounted to ¥1,037,789,459.81, an increase from ¥891,627,601.69 in the previous year[18] Research and Development - Research and development expenses totaled CNY 21,503,347.58, a decrease of 10.16% year-on-year, with R&D expenses accounting for 7.69% of operating revenue[6] - The company is actively engaged in the research and development of various veterinary vaccines, with multiple products in different stages of clinical trials and laboratory research[15] - The company has submitted clinical trial applications for several new vaccines, including a dual inactivated vaccine for swine fever and pseudorabies, indicating a focus on expanding its product portfolio[15] - The company invested a total of RMB 10,865,581.84 in the clinical trial of the genetically engineered live vaccine for pseudorabies in pigs[14] - The company reported an investment of RMB 13,267,253.59 in the laboratory research of the genetically engineered live vaccine for infectious bovine rhinotracheitis[14] - The company has a total of 10 ongoing research projects related to veterinary products, with varying stages of progress and investment amounts[14] Shareholder Information - The company had a total of 7,887 common shareholders at the end of the reporting period[12] - The top shareholder, Wuhan Huazhong Agricultural Assets Management Co., Ltd., held 16.73% of the shares, totaling 78,004,310 shares[12] - The company has a total of 10 major shareholders, with specific shareholding details disclosed in the report[13] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[20]

Financial Performance - The company reported a total revenue of 1,001.27 million RMB, a year-on-year decrease of 9.22%[1] - The main product, pig vaccines, generated revenue of 937.43 million RMB, down 11.30% compared to the previous year[1] - Total revenue decreased by 18.64% to 8,877,332.39 million RMB compared to the previous year[9] - The company reported a total revenue of 1.5 billion in 2022, representing a year-over-year growth of 10%[100] - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[103] - The company reported a revenue of CNY 1,001,267,679.90 in 2022, a decrease of 9.22% compared to CNY 1,103,021,004.82 in 2021[196] - Net profit attributable to shareholders was CNY 409,518,439.60, down 28.25% from CNY 570,741,302.79 in the previous year[196] Operating Costs and Expenses - The company's operating costs increased by 18.62% to 264.23 million RMB[1] - Sales expenses rose by 19.38% to 159,884,797.12 RMB, while management expenses decreased by 10.78%[15] - The increase in costs is attributed to the second phase of the animal biological product industrialization project, leading to higher depreciation and energy costs[35] - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year[100] - Operating expenses were reduced by 5% compared to the previous year, contributing to overall profitability[100] Research and Development - The company has invested nearly ¥240 million in R&D over the past three years, with 65 ongoing projects in 2022, including significant progress on the "Pig δ Coronavirus Inactivated Vaccine" project[36][38] - The company has obtained 41 national new veterinary drug certificates, with several innovations filling domestic gaps[38] - The company reported a research and development investment of 26,723.37 million RMB, accounting for 15.04% of operating revenue and 4.81% of net assets[48] - The company’s R&D investment as a percentage of operating revenue for the reporting period was 10.26%[48] - The company has established a leading R&D team in the domestic market and has obtained multiple new veterinary drug registration certificates, positioning itself at the forefront of the industry[177] Market and Sales Performance - The sales volume of pig live vaccines was 300,532.60 thousand doses, a decrease of 12.02% year-on-year[3] - The sales volume of pig inactivated vaccines increased by 12.22% to 480,079.60 thousand milliliters[3] - Revenue from pet vaccines increased significantly by 134.89% year-over-year, amounting to approximately ¥6.75 million, although the gross margin was negative at -1.58%[34][35] - The company is focused on expanding its market presence through the development of innovative products and potential acquisitions[28] - The company is expanding its market presence in pet vaccines, diagnostics, and ecological products, contributing to overall revenue growth[35] Inventory and Cash Flow - The company experienced a significant increase in inventory levels, particularly for pig live vaccines, which rose by 75.71%[3] - Net cash flow from operating activities decreased by 20.25% to 423,708,722.97 RMB[16] - The company extended the collection period for high-quality customers, impacting cash flow from operating activities[199] Acquisitions and Investments - The company acquired 95% of Wuhan Zhule Tianyuan Ecological Agriculture Co., Ltd., expanding its consolidation scope[10] - The company invested 52,750,000 RMB in equity investments during the reporting period, a decrease of 66.51% compared to the previous year[60] - The company plans to issue A-shares to specific targets, with a focus on enhancing sustainable development and market competitiveness[130] Governance and Management - The company has established a robust organizational structure, maintaining independence from the controlling shareholder in business, assets, personnel, and finance[82] - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with corporate governance regulations[81] - The company has implemented various information disclosure management systems to ensure timely and accurate communication with investors[82] Risks and Challenges - The company faced challenges due to the dual impact of African swine fever and COVID-19, leading to a reduction in customer numbers and overall revenue[2] - The company faces risks related to declining sales gross margins due to increased market competition and potential price reductions in vaccine products[159] - The company acknowledges the risks associated with regulatory changes in the veterinary drug industry, which could delay R&D progress and increase production costs[164] Future Outlook - The company provided a forward guidance of 1.8 billion in revenue for the next fiscal year, indicating a growth target of 20%[100] - The company plans to launch new products in the next quarter, targeting a 15% increase in market share[95] - The company aims to achieve a revenue growth target of 10% for the upcoming fiscal year[95]

Financial Performance - The company's operating revenue for Q3 2022 was ¥292,893,681.48, representing a year-on-year increase of 26.97%[8] - The net profit attributable to shareholders for Q3 2022 was ¥124,316,091.34, an increase of 24.61% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥116,998,185.12, reflecting a 19.49% increase year-on-year[8] - Total operating revenue for the first three quarters of 2022 was CNY 686,519,778.45, a decrease from CNY 775,730,840.29 in the same period of 2021[41] - Net profit for the third quarter of 2022 was CNY 283,242,940.68, down from CNY 385,906,499.83 in the same quarter of 2021[44] - Basic earnings per share for the third quarter of 2022 were CNY 0.61, compared to CNY 0.83 in the same quarter of 2021[47] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥4,112,287,808.95, a 10.39% increase from the end of the previous year[11] - The equity attributable to shareholders at the end of Q3 2022 was ¥3,362,357,143.43, which is a 6.62% increase compared to the previous year[11] - Total liabilities as of the reporting date were CNY 747,676,688.12, an increase from CNY 571,411,688.95 in the previous year[38] - Non-current liabilities totaled CNY 109,565,365.15, compared to CNY 79,167,052.81 in the previous year, reflecting growth[38] - The total current liabilities increased to CNY 70,057,000.00 from CNY 18,028,402.78, showing a significant rise of about 288.5%[36] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥331,129,993.39, a decrease of 30.11% compared to the previous year[11] - The net cash flow from operating activities was 331,129,993.39, a decrease of 30% compared to 473,820,698.63 from the previous period[51] - Cash inflow from investment activities totaled 1,087,055,180.09, up from 909,195,036.22, indicating a growth of approximately 19.6%[51] - The net cash flow from investment activities was -342,129,625.01, slightly worse than -314,670,837.11 from the previous period[51] - Cash inflow from financing activities was 79,984,913.26, down from 94,377,295.80, reflecting a decline of about 15.3%[52] - The net cash flow from financing activities was -84,584,534.30, an improvement compared to -115,994,664.61 in the previous period[52] Research and Development - The R&D investment totaled ¥20,721,031.10 for Q3 2022, an increase of 11.80% compared to the same period last year[11] - The R&D investment as a percentage of operating revenue was 7.07%, a decrease of 0.96 percentage points year-on-year[11] - The company has established a cooperation framework agreement with Huazhong Agricultural University for future R&D projects[24] - The company invested a total of RMB 9,630,743.93 in the research of the genetically engineered live vaccine for pseudorabies, with ongoing laboratory research[25] - The company has a cumulative investment of RMB 12,283,223.40 in the research of the genetically engineered live vaccine for infectious bovine rhinotracheitis, currently in laboratory research[25] - The company is actively involved in laboratory research for various vaccines, including the rabies virus inactivated vaccine, which is part of its ongoing product development strategy[27] Product Development - The company has obtained 39 new veterinary drug registration certificates, with 29 obtained through collaboration with Huazhong Agricultural University[24] - The company has registered 10 new veterinary drugs through third-party collaborations[24] - The company has invested RMB 8,100,512.69 in the research of the inactivated vaccine for porcine circovirus type 2 and Actinobacillus pleuropneumonia, with new veterinary drug registration achieved[25] - The company has invested RMB 468,859.81 in the research of the live vaccine for Mycoplasma bovis, with new veterinary drug registration achieved[25] - The company has invested RMB 616,943.07 in the research of the inactivated vaccine for porcine delta coronavirus, with new veterinary drug registration achieved[25] - The company is pursuing clinical trials for new vaccines, including the dual inactivated vaccine for swine fever and pseudorabies, indicating a focus on innovation and market expansion[36] Shareholder Information - The company has a total of 10,915,000 shares held by the controlling shareholder, Mu Yuan Industrial Group Co., Ltd.[23]

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching CNY 200 million, representing a growth of 25% year-over-year[19]. - The company's operating revenue for the first half of the year was ¥393,626,096.97, a decrease of 27.78% compared to ¥545,046,578.13 in the same period last year[26]. - The net profit attributable to shareholders was ¥159,113,293.81, down 44.39% from ¥286,142,392.70 year-on-year[26]. - The basic earnings per share decreased by 45.16% to ¥0.34 from ¥0.62 in the previous year[27]. - The net cash flow from operating activities was ¥185,552,251.93, a decline of 33.35% compared to ¥278,410,459.53 last year[26]. - The company achieved a total revenue of 256.32 million, with a net profit of 221.47 million, reflecting a strong performance in the first half of 2022[120]. - The company reported a revenue of 393.63 million RMB for the first half of 2022, a decrease of 27.78% year-on-year[184]. - The net profit attributable to the parent company was 159.11 million RMB, down 44.39% compared to the previous year[184]. Research and Development - The company has allocated CNY 30 million for research and development in innovative technologies for the upcoming fiscal year[19]. - R&D investment accounted for 11.74% of operating revenue, an increase of 4.72 percentage points compared to 7.02% last year[30]. - The company has invested over 180 million RMB in R&D from 2019 to 2021, with over 46 million RMB invested in the first half of 2022, supporting 62 ongoing projects[80]. - The company has applied for 120 national invention patents, with 53 granted, including 7 granted in the first half of 2022[84][85]. - The company has established a high-level R&D center and a complete technology innovation platform, recognized by national authorities[128]. - The R&D team consists of 257 professionals covering various fields related to veterinary biological products, which supports the company's continuous innovation and development[135]. - The company has established a research and development system that combines independent innovation with industry-university-research cooperation, resulting in 49 approved veterinary drug products, with over 30 derived from its research achievements[135]. Product Development - New product development includes the launch of a novel vaccine, which is expected to contribute an additional CNY 50 million in revenue by the end of the year[19]. - The company has developed a diverse range of 49 veterinary biological products, focusing on high-quality and high-value animal biological products[37]. - New product developments include various vaccines for pigs, emphasizing safety and efficacy, such as the live vaccine for pseudorabies and the inactivated vaccine for pseudorabies[38]. - The company has launched a series of inactivated vaccines for pigs, including the Porcine Circovirus Type 2 vaccine, which features advanced antigen culture technology and high antibody levels[42]. - The company has developed a dual-subunit vaccine for Streptococcus suis and Actinobacillus pleuropneumonia, which has received a new veterinary drug certificate[79]. - The company is preparing for new veterinary drug registration for the porcine circovirus type 2 recombinant baculovirus inactivated vaccine, which has completed clinical trials[75]. - The company has successfully developed a rabies vaccine with an investment of $1.5 million, which is now in the industrial production phase, reinforcing its position in the veterinary vaccine sector[106]. Market Strategy - The company is planning to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[19]. - The company employs a "sales-driven production" model, aligning production plans with sales targets and maintaining safety stock[50]. - The company’s direct sales model targets large-scale pig farming enterprises with a minimum of 5,000 sows, ensuring a focused approach to customer selection[51]. - The sales strategy employs a "direct sales + distribution" model, effectively expanding the company's market influence and service radius[140]. - The company has established long-term stable partnerships with major enterprises in the industry, enhancing its market influence[144]. Financial Risks and Challenges - The decline in revenue and profit was primarily due to low pig prices and reduced sales volume as farmers' willingness to vaccinate decreased[30]. - The company faces risks related to the administrative licensing of its operational qualifications, which are essential for continuing its production and sales of veterinary biological products[161]. - The company is exposed to risks from the cyclical nature of pig prices, which can impact the willingness of farmers to purchase vaccines during low price periods[172]. - The sales gross margin for the company's pig vaccines has shown a decline from 83.74% in 2021 to 72.69% in the first half of 2022, indicating potential risks in profitability due to market competition[168]. Operational Efficiency - The gross profit margin for the first half of 2022 was reported at 45%, an improvement from 40% in the same period last year[19]. - Operating costs increased by 7.75% to 107.51 million RMB, attributed to increased depreciation from new fixed assets[185]. - The company continues to optimize its product structure and improve cost efficiency to enhance its resilience against market risks[145]. - The company has established a comprehensive quality management system to mitigate product quality risks, which are critical for maintaining brand reputation[166]. Acquisitions and Collaborations - A strategic acquisition of a local biotech firm is in progress, which is anticipated to enhance the company's R&D capabilities and product offerings[19]. - The company has obtained 29 new veterinary drug registration certificates through collaboration with Huazhong Agricultural University[180]. - The company faces risks related to the termination of cooperation with Huazhong Agricultural University, which could negatively impact product development[178].